

# Gender differences in retention and survival on antiretroviral therapy of HIV-1 infected adults in Malawi

Katie Taylor-Smith<sup>1</sup>, Hannock Tweya<sup>2</sup>,  
Anthony Harries<sup>3</sup>, Erik Schoutene<sup>4</sup>,  
Andreas Jahn<sup>4</sup>

1. Medecins sans Frontieres, Medical Department (Operational Research), Brussels Operational Center, Brussels, Belgium.

2. The Lighthouse Trust, Kamuzu Central Hospital, Lilongwe, Malawi.

3. International Union against Tuberculosis and Lung Disease, Paris, France.

4. Ministry of Health, Department of HIV/AIDS.

## Abstract

### Background

There is currently a dearth of knowledge on gender differences in mortality among patients on ART in Africa.

### Methods

Using data from the national ART monitoring and evaluation system, a survival analysis of all healthcare workers, teachers, and police/army personnel who accessed ART in Malawi by June, September and December 2006 respectively, was undertaken. Gender differences in survival were analysed using Kaplan-Meier estimates and rate ratios were derived from Poisson regression adjusting for confounding.

### Results

4670 ART patients (49.8% female) were followed up for a median of 8.7 months after starting ART. Probability of death was significantly higher for men than women ( $p < 0.001$ ). Controlling for age, WHO clinical stage and occupation, men experienced nearly 2 times the mortality of women RR 1.90 [95% CI: 1.57-2.29]. A higher proportion of men initiated ART in WHO stage 4 ( $p < 0.001$ ).

### Conclusion

Among healthcare workers, teachers, police/army personnel, men have higher mortality on ART than women. Possible reasons are unclear but could be biological or because men present for ART at a later clinical stage or have poorer adherence to therapy. Improving early access to ART may reduce mortality, especially among men. A gender difference in adherence to therapy needs further investigation.

### Introduction

Since the advent of ART, mortality rates for people living with HIV/AIDS have decreased substantially both in resource-rich<sup>1,2</sup> and resource-limited settings<sup>3,8</sup> with conflicting reports about gender-related differences in mortality<sup>9-16</sup>. Where differences have been reported, little is known about the reasons.

Identifying whether men and women benefit equally from ART and ascertaining the reasons underlying any difference could inform strategies designed to address these differences and optimise ART delivery. This is especially important in resource limited settings like Malawi (where ART scale-up is a major focus), and particularly among specific occupational sub-groups of the population who contribute significantly to the socio-economic development of the country and whose skill-base continues to be depleted by HIV/AIDS. Previous studies have considered the general population rather than

specific occupational groups.

Previous studies in Malawi focused on the specific occupational groups of health care workers<sup>17</sup> teachers<sup>18</sup> army<sup>19</sup> and police personnel<sup>20</sup> separately reporting outcomes in relation to demographic and clinical variables. As the same systems of recording and data collection were used for each study, we decided to combine the databases of the four studies to determine whether there is a gender difference in mortality among adults receiving ART in Malawi, and to explore possible reasons for any difference among healthcare workers, teachers, army and police personnel.

### Materials and Methods

#### Ethics Statement

General measures are provided in all ART facilities to ensure patient confidentiality, consent for HIV testing, and counselling and support for those who receive a positive HIV test result. Data for this study did not include any personal identifiers and were analysed anonymously. The Malawi National Health Science Research Committee provides general oversight and approval for the collection and use of routine programmatic data for monitoring and evaluation, as was the case with this study.

Formal ethical approval was therefore not required from the Malawi Research Committee and as such, no application was made for ethical approval from either Medecins sans Frontieres or The International Union against Tuberculosis and Lung Disease.

#### Background

Malawi is among the poorest countries in sub-Saharan Africa with an estimated population of about 13 million<sup>21</sup>. Like other countries in the region, it has experienced a severe HIV epidemic. The national HIV adult prevalence is estimated at about 12% with 810,000 adults living with HIV/AIDS<sup>22</sup>.

Described previously,<sup>23</sup> ART scale-up in Malawi began in June 2004 utilising a national roll-out programme of free ART to all public-sector facilities. ART scale up in the private sector has followed the same process with private treatment offered at a subsidised cost. As of September 2008, there were 170 facilities in the public health sector and 44 sites in the private sector providing ART to over 135,000 patients<sup>24</sup>.

Patients are eligible for ART if they are HIV-seropositive, understand the implications of starting ART and either present in WHO Clinical Stage 3 or 4 or have a CD4-lymphocyte count of 250/mm<sup>3</sup> or less (irrespective of WHO stage)<sup>25</sup>. Without the equipment to perform CD4-lymphocyte counts, most clinics use clinical staging alone to determine ART eligibility.

Malawi uses a standardised ART approach: use of one generic fixed dose combination of stavudine (d4T), lamivudine (3TC) and nevirapine (NVP). There are two alternative first line regimens for patients with serious side effects, substituting d4T with zivudine (AZT) or NVP with efavirenz (EFV). Two standard proteinaseinhibitor based second line regimens are available for adults and children with drug failure.

A nationally standardised process of registration, monitoring

and reporting of cases and outcomes is used<sup>26</sup>. Using one master card per patient and one ART register per ART facility<sup>23</sup> patient demographic details, occupation, ART start date and WHO stage together with any stage defining conditions at ART initiation, are recorded. After starting ART, patients are followed up at two weeks and then at monthly intervals for clinical assessment and ARV dispensing. Monthly visits are recorded on the master card and patient outcomes are updated quarterly in the ART register. Standardised follow-up outcomes are defined as: alive and on ART (patient alive and on ART at the facility where he/she is registered); dead (patient who has died from any cause while on ART); lost to follow-up (patient on ART who has not attended the ART clinic for 3 months or longer for no known reason and cannot be traced); stopped treatment (patient who is known to be alive and has stopped ART for any reason); transferred out (patient who has transferred-out permanently to another treatment facility). Active follow-up of patients who default is not mandatory due to limited resources but most facilities routinely attempt to trace patients who have failed to attend their scheduled appointment.

At the end of every quarter, each facility conducts a cohort analysis of patients newly registered during the quarter and of all patients ever registered at the facility. The Ministry of Health's Department of HIV and AIDS and its partners conduct quarterly supervisory and monitoring visits to all public sector ART facilities in the country.

They check the completeness of the ART registers, cross-check the data recorded on the patient master cards with the data entered in the ART registers and cross-check the cohort analysis<sup>23</sup>. In the private sector a similar supervisory and monitoring system is conducted.

### **Data Collection**

During three rounds of quarterly supervision visits to all public and private ART facilities between July 2006 and March 2007, individual level patient data were collected for the following occupational cohorts: healthcare workers, teachers and army/police personnel<sup>17,18,19,20</sup>. The following patient data were transcribed from the ART registers onto structured data collection forms: sex, age, date and WHO clinical stage at ART initiation together with selected stage defining conditions, date and reason for termination of observation at the respective facility (alive on ART at end of observation, transferred to another facility, stopped treatment ('ART stop'), lost to follow up, death). Observations were censored depending on the time of data collection: healthcare workers (30 June 2006); teachers (30 September 2006); army and police personnel (31 December 2006).

### **Data Analysis**

Data were double entered in Microsoft Access and analysed using STATA version 10. Death was used as the failure event for the analysis of mortality rates. Due to the incomplete ascertainment of deaths and in order to control for potentially differential ascertainment of death by gender, a separate analysis was done combining death, ART stop and loss to follow-up as the failure event ('ART drop-out'). For the person years denominator, patients were generally considered to come under observation at the time of ART initiation. For 718 patients who had initiated ART before implementation of the standard M&E tools in June 2004, the 1st of June 2004 was used as the observation start date, but their previous exposure time on ART was accurately

accounted for in the time at risk. Observations ended at the end of the quarter of data collection or at the time of death, ART stop, transfer-out to another facility or loss to follow-up. Twenty-two cases were excluded because the date of ART initiation or date of termination of observation, were inconsistent or incomplete.

Gender was the main exposure of interest. Age, clinical stage at ART initiation, specific stage defining conditions, occupation and type of ART facility were considered as potential confounders in the association of gender with mortality and ART drop-out. The strength of association between gender and other background variables was measured using the X2 test. Cumulative survival probabilities were estimated using the Kaplan-Meier method and survival between men and women was compared using the log-rank test. Rate ratios were calculated for mortality and 'ART drop-out'. Poisson regression models were used to compare rates between men and women, adjusting for age and WHO clinical stage at ART initiation. P-values were derived from the Wald test and 95% confidence intervals for point estimates are given throughout.

## **Results**

### ***Characteristics of the study population and gender differences in death***

Of a total of 4692 patients receiving ART between June 2004 and December 2006, 4670 were included in the analysis. Of these, 2346 (50.2%) were men. Women were on average 3 years younger than men at ART initiation (median age 39 years for men (interquartile range (IQR) 35-44 years) and 36 years for women (IQR 32-42 years)).

Men initiated ART in clinically more advanced stages than women. A total of 731 (31.2%) men and 577 (24.8%) women were in WHO clinical stage 4 at ART initiation ( $p < 0.001$ ); 354 (15.1%) men and 394 (17.0%) women were in stage 1 or 2 with a CD4 count below 250 cells/ $\mu$ l (Table 1). Clinical stage at ART initiation was missing for 37 patients (0.8%). More than twice as many men presented with Kaposi's sarcoma at ART initiation (197 men (8.4%) versus 95 women (4.1%),  $p < 0.001$ ), but similar proportions of men and women had pulmonary and extra-pulmonary tuberculosis. (Table 1). Most patients (4413 patients, 94.5%) were from public sector clinics, but the proportion of private sector patients was higher among women (37 men (1.6%) versus 88 women (3.8%),  $p < 0.0001$ ).

A total of 547 patients died, 20 stopped ART and 288 were lost to follow-up in 4,439 person-years of observation (PYO), resulting in a mortality rate of 123.2 per 1000 PYO [95% CI, 113.3-134.0] and an 'ART drop-out' rate of 192.6 per 1000 PYO [95% CI, 180.1-206.0]. Mortality was 402.3/1000 PYO [95% CI, 356.7-453.6] in month 0-2 after ART initiation, 130.0/1000 PYO [95% CI, 135.1-190.5/1000 PYO] in month 3-5, 70.2/1000 PYO [95% CI, 56.6-87.0/1000 PYO] in month 6-11 and 59.8/1000 PYO [95% CI, 44.5-80.3/1000 PYO] in month 12-17. Table 2 shows that mortality and ART drop-out rates declined in a very similar fashion after ART initiation.

Median follow-up time was 9.0 months for women (range 0.03 - 60.5 months) and 8.4 months for men (range 0.03 - 63.1 months). A total of 341 deaths were recorded in 2171 PYO among men, resulting in a mortality rate of 157.1/1000 PYO [95%CI, 141.3-174.7/1000 PYO]; 206 deaths were recorded in 2268 PYO among women, resulting in a

mortality rate of 90.8/ 1000 PYO [95%CI: 79.3-104.1]. ART drop-out rates were 228.5/ 1000 PYO [95% CI: 209.2-249.5] among men and 158.3/ 1000 PYO [95% CI: 142.8-175.6] among women. The cumulative probability of survival at 3, 6, 12 and 18 months after ART initiation was 90%, 87%, 83% and 80% for men and 94%, 92%, 90% 88% for women. Figure 1 shows the cumulative survival probabilities for men and women, illustrating the significantly lower survival among men ( $p < 0.001$ ). Mortality rate ratios, comparing men with women, were 1.78 [95% CI: 1.39-2.29], 1.37 [95% CI: 0.97-1.94], 1.99 [95% CI: 1.26-3.14] and 1.84 [95% CI: 0.99-3.39] at 0-2 months, 3-5 months, 6-11 months and 12-17 months after ART initiation. Rate ratios for ART drop-out, comparing men with women within the respective intervals, were 1.58 [95% CI: 1.29-1.94], 1.14 [95% CI: 0.86-1.51], 1.50 [95% CI: 1.06-2.13] and 1.53 [95%CI: 0.99-2.35]. Table 2 shows mortality and ART drop-out rates according to different background variables. Mortality and ART dropout were much higher among patients in stage 4 than stage 3 (RR 1.98 [95% CI: 1.67-2.37] and RR 1.58 [95% CI: 1.37-1.83] respectively). Similarly, Kaposi's sarcoma was associated with over a 2 fold increase in mortality (RR 2.29 [95% CI: 1.7-2.96] and ART drop out (RR 2.07 [95% CI: 1.67-2.56]). Mortality and ART dropout were lower among patients from private sector facilities compared to public sector facilities (RR 0.15 [95% CI: 0.04-0.60] and RR 0.14 [95% CI: 0.05-0.44] respectively) although the private sector was a very small group ( $n=125$ ). Similarly mortality and ART drop-out were lower among patients who had initiated therapy before the roll-out of free ART (RR 0.38 [95% CI: 0.30-0.47] and RR 0.58 [95% CI: 0.49-0.68] respectively). Mortality and ART drop-out were similar across different age bands and also among the different occupational groups (apart from army personnel who had a lower ART drop-out (RR 0.70 [95% CI: 0.56-0.88]).

Adjusting for different background characteristics showed that increased mortality among men was partly explained by age, clinical stage and occupation. However, adjusted mortality and ART drop-out rates among men were still approaching nearly two times that of women (RR 1.90 [95% CI: 1.57-2.29] and RR 1.66 [95% CI: 1.43- 1.92] respectively) (Table 2). Adjusted mortality rate ratios, comparing men with women, were RR 1.85 [95% CI: 1.42-2.40], RR 1.44 [95% CI: 1.00-2.06], RR 2.11 [95%CI: 1.33-3.34] and RR 1.94 [95%CI: 1.04-3.60] at 0-2 months, 3-5 months, 6-11 months and 12-17 months after ART initiation. There was no statistical evidence that these rate ratios differed across the different time intervals ( $p=0.50$ ).

## Discussion

Given the conflicting reports about gender differences in mortality of patients on ART in Africa [13-16], this study aimed to determine whether a difference exists and if so possible reasons for it. Whereas previous studies have considered this gender difference among individuals on ART in the general population, this study focussed on individuals on ART from specific occupational groups.

Among healthcare workers, teachers, army and police personnel on ART in Malawi, men were found to experience higher mortality rates and higher ART drop out rates than women after adjusting for age at ART initiation, WHO clinical stage and occupation. By considering these two outcomes separately, we can assume that if all defaulters have actually died then men have nearly 1.7 times higher mortality than

women, whereas if all defaulters have silently transferred to another facility and are actually alive on ART elsewhere, then men have 1.9 times higher mortality than women.

There are several possible explanations for higher male mortality. First, increased mortality among male ART patients in our study may have been due or partly due to poorer adherence to therapy compared with women. Increased mortality among male ART patients in Africa has previously been reported, including two reports from Malawi<sup>14,15</sup>. In one of these reports, the authors suggested that this may be due to men having poorer compliance to therapy, as indicated by their higher loss to follow-up (18.6% versus 13.0% for women)<sup>15</sup>. However, using loss to follow-up as a measure of adherence to therapy is actually misleading. Loss to follow-up is a measure of clinic retention and does not necessarily reflect adherence to treatment.

For instance, a patient lost to follow-up (i.e. not retained at the clinic) might have transferred to another site and might be taking his/her drugs perfectly regularly.

Another patient presenting perfectly at each appointment might have very poor adherence in terms of taking his/her pills.

Secondly, increased male mortality may be due to men starting ART at more advanced stages of AIDS than women. We controlled for level of disease progression using WHO clinical stage but it is likely that there was considerable heterogeneity of immunological stage within the clinical stages. Increased mortality in men may therefore have been due to residual confounding from more advanced disease at the time of treatment initiation. However, one finding in our study suggests that this may not be the case. Given that advanced immunodeficiency is known to be among the most important risk factors for early mortality in patients on ART<sup>3,6,13,15,27,29</sup> one might hypothesise that if men are experiencing a higher mortality than women due to delayed ART initiation, gender differences in early mortality may be much greater than differences in later mortality. In fact, across different time intervals, mortality rate ratios comparing men and women were not statistically different. It must however be highlighted that a comparison of death rates between men and women beyond 6 months in this study is difficult due to relatively few deaths occurring beyond this time and therefore lack of statistical power to make a comparison.

Nevertheless, delayed ART initiation among men is still an issue that probably warrants further examination. Prevention of mother to child transmission (PMTCT) programmes have been proposed as an explanation for why some women present for ART earlier than men. However, only one woman was recorded as starting ART for PMTCT in this current study, and we do not think that this explains these particular findings. Still, it is likely that women generally access health services more frequently than men because of their children (e.g. for child vaccinations, accessing treatment for sick children) and this may partly underpin why they generally access ART earlier than men. Delayed ART initiation among men may also be explained by psychosocial factors such as stigma, pride and fear. A previous study from Malawi, also reporting a delay in ART initiation among men, suggested that this may be due to male dignity and preservation of masculinity, a feature of Malawian culture, supported by anecdotal observation and qualitative study<sup>15</sup>.

Third, there may be a biological sex difference in the pharmacology and drug response to ART. In this study,

all patients starting ART were started on a fixed dose combination of stavudine, lamivudine and nevirapine. In a previous study investigating the pharmacokinetic and pharmacodynamic sex differences of specific antiretroviral drugs including lamivudine, women had 1.6 fold higher plasma concentrations of lamivudine triphosphate than men and achieved a viral load reduction twice as fast as men [30]. Although these data were based on the evaluation of only 33 patients, other studies have also reported that women reach higher plasma concentrations with a number of antiretroviral drugs compared to men<sup>31,32</sup>. It is therefore possible that the gender difference in mortality found in this study may be related to higher drug levels that are achieved in women.

Finally, there may be other factors involved. We have little information in Malawi or in other resource-poor settings about the comparative rates of cigarette smoking or alcohol consumption between men and women on ART. Yet these may affect ART outcomes. There are suggestions that smoking may contribute to increased morbidity and mortality in HIV-infected populations<sup>33</sup> and that alcohol may be strongly associated with non-adherence to ART and worse virological outcomes<sup>34,35</sup>. The finding in this study, that HIV-infected women on ART tend to live longer than HIV-infected men on ART, must also be considered in light of the fact that women also live longer than men in the general population. In Malawi, life expectancy for men is 49 years versus 51 years for women<sup>21</sup>. Although small, this intrinsic sex related biological difference may account for at least some of the gender difference seen in mortality.

The study has several strengths. First, the databases were constructed from national surveys using data from a rigorously supervised monitoring and evaluation system and should therefore be nationally representative of all healthcare workers, teachers, police and army personnel on ART in Malawi. Second, by restricting the study to patients in specific occupations, important social factors including healthcare seeking behaviour and socio-economic status should have been controlled for. Third, gender differences in mortality and ART drop out were very similar suggesting that death ascertainment was non differential between men and women, and finally, the defaulter rate in this analysis is lower than the national average, because follow-up ascertainment was likely better in these occupational cohorts than for the total national cohort<sup>36</sup>.

There were, however, several limitations of the study. CD4 count and viral load measurements were not performed at the start and during the course of ART which may otherwise have offered an explanation for the gender difference in mortality and could have been used to give a clinical indication of adherence to therapy. There was no available data for body mass index, adherence to treatment and changes in ART regimen (the analysis being based on an 'intention to treat' analysis) so residual confounding from any of these variables could have meant that the study under- or overestimated the gender difference in mortality. In addition, data on death were noncause specific so some deaths could have been non-HIV related. The study included patients who had transferred out; this could potentially have led to a duplication of observation time which would have led to an underestimation of mortality rates.

However since transfer out rates were very small and very similar for men and women, the effect of this is likely to be small. Finally, our findings can only be generalised to

healthcare workers, teachers, army and police personnel in Malawi rather than the general population.

## Conclusion and recommendations

Among healthcare workers, teachers, police and army personnel in Malawi, HIV-infected men on ART experience significantly higher mortality than women. This gender difference may be due to men starting ART at a later clinical stage than women (although there is some evidence to doubt this); it may be due to poorer compliance to therapy among men than women; it may be biological or due to other factors such as cigarette smoking and alcohol.

To improve early access one strategy may be to identify patients with advanced clinical disease and implement a system to fast track them onto treatment. It has been suggested that identification of these 'high risk' patients could also be facilitated by other disease programmes such as tuberculosis treatment programmes<sup>27</sup>. With pulmonary tuberculosis (PTB) one of the most common manifestations of WHO stage 3 disease in Malawi (32% of patients in this study who started ART at WHO stage 3 presented with PTB), TB treatment programmes are potentially a key point of access to ART services. In Malawi the national TB programme works in collaboration with the ART programme to identify and refer these patients appropriately. Efforts to strengthen this referral process may facilitate earlier access to treatment. In addition, using qualitative approaches to ascertain why some men delay ART initiation would enable appropriate strategies to be deployed to try and encourage earlier access.

Secondly, the issue of adherence to therapy possibly being poorer among men also needs further study. Thirdly, if some of the gender difference in mortality is due to a gender difference in the pharmacology and drug response to ART, this needs to be verified in future studies first before the practical implications of altering drug dosage according to sex are given any due consideration. Fourth, the effects of cigarette smoking and alcohol and other determinants in relation to gender should be investigated. Finally, it is believed that mortality during screening before people are started on ART in Malawi is very high; whether there are differences in survival between men and women at this stage poses yet another question.

## Acknowledgments

The data collected for the healthcare workers, teachers, army and police operations studies were supported through an anonymous donor and linked to routine supervisor visits carried out by the Department of HIV and AIDS in the Malawi Ministry of Health. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

## Authors contributions

Anthony Harries, Erik Schouten and Andreas Jahn were involved in the ART monitoring and evaluation over the period in this study and participated in data collection. Anthony Harries, Erik Schouten, Kelita Kamoto, Sam Phiri and Andreas Jahn designed the study. Katie Taylor-Smith, Hannock Tweya, Anne Ben-Smith and Andreas Jahn analysed and interpreted the data. Katie Taylor-Smith, Hanock

Tweya, Anthony Harries and Andreas Jahn wrote the first draft. The second and subsequent drafts were reviewed and critically appraised by all co-authors. All authors have seen

and approved the final draft for submission.

## References

1. Detels R, Munoz A, McFarlane G, et al. Effectiveness of potent antiretroviral therapy on time to AIDS and death in men with known HIV infection duration. Multicenter AIDS Cohort Study Investigators. *Jama* 1998; 280: 1497-1503.
2. CASCADE Collaboration. Survival after introduction of HAART in people with known duration of HIV-1 infection. The CASCADE Collaboration. Concerted Action on SeroConversion to AIDS and Death in Europe. *Lancet* 2000; 355: 1158-1159.
3. Weidle PJ, Malamba S, Mwebaze R, et al. Assessment of a pilot antiretroviral drug therapy programme in Uganda: patients' response, survival, and drug resistance. *Lancet* 2002; 360: 34-40.
4. Wester CW, Kim S, Bussmann H, et al. Initial response to highly active antiretroviral therapy in HIV-1C-infected adults in a public sector treatment program in Botswana. *J Acquir Immune Defic Syndr* 2005; 40: 336-343.
5. Coetzee D, Hildebrand K, Boulle A, et al. Outcomes after two years of providing antiretroviral treatment in Khayelitsha, South Africa. *Aids* 2004; 18: 887- 895.
6. Stringer JS, Zulu I, Levy J, et al. Rapid scale-up of antiretroviral therapy at primary care sites in Zambia: feasibility and early outcomes. *Jama* 2006; 296: 782- 793.
7. Lawn SD, Myer L, Harling G, Orrell C, Bekker LG, Wood R. Determinants of mortality and nondeath losses from an antiretroviral treatment service in South Africa: implications for program evaluation. *Clin Infect Dis* 2006; 43: 770-776.
8. Jahn A, Floyd S, Crampin AC, et al. Population-level effect of HIV on adult mortality and early evidence of reversal after introduction of antiretroviral therapy in Malawi. *Lancet* 2008; 371: 1603-1611.
9. Perez-Hoyos S, del Amo J, Muga R, et al. Effectiveness of highly active antiretroviral therapy in Spanish cohorts of HIV seroconverters: differences by transmission category. *Aids* 2003; 17: 353-359.
10. Hall HI, McDavid K, Ling Q, Sloggett A. Determinants of progression to AIDS or death after HIV diagnosis, United States, 1996 to 2001. *Ann Epidemiol* 2006; 16: 824-833.
11. Moore AL, Kirk O, Johnson AM, et al. Virologic, immunologic, and clinical response to highly active antiretroviral therapy: the gender issue revisited. *J Acquir Immune Defic Syndr* 2003; 32: 452-461.
12. d'Arminio A, Sabin CA, Phillips AN, et al. (2004) Cardio and cerebrovascular events in HIV-infected persons. *Aids* 2004; 18: 1811-1817.
13. Calmy A, Pinoges L, Szumilin E, Zachariah R, Ford N, Ferradini L. Generic fixed-dose combination antiretroviral treatment in resource-poor settings: multicentric observational cohort. *Aids* 2006; 20: 1163-1169.
14. Ferradini L, Jeannin A, Pinoges L, et al. Scaling up of highly active antiretroviral therapy in a rural district of Malawi: an effectiveness assessment. *Lancet* 2006; 367: 1335-1342.
15. Chen SC, Yu JK, Harries AD, et al. Increased mortality of male adults with AIDS related to poor compliance to antiretroviral therapy in Malawi. *Trop Med Int Health* 2008; 13: 513-519.
16. Etard JF, Ndiaye I, Thierry-Mieg M, et al. Mortality and causes of death in adults receiving highly active antiretroviral therapy in Senegal: a 7-year cohort study. *Aids* 2006; 20: 1181-1189.
17. Makombe SD, Jahn A, Tweya H, et al. A national survey of the impact of rapid scale-up of antiretroviral therapy on health-care workers in Malawi: effects on human resources and survival. *Bull World Health Organ* 2007; 85: 851-857.
18. Makombe SD, Jahn A, Tweya H, et al. A national survey of teachers on antiretroviral therapy in Malawi: access, retention in therapy and survival. *PLoS ONE* 2007; 2: e620.
19. Banda AC, Makombe SD, Jahn A, et al. Antiretroviral therapy in the Malawi defence force: access, treatment outcomes and impact on mortality. *PLoS ONE* 2008; 3: e1445.
20. Makombe S, Jahn A, Tweya H, et al. The impact of national antiretroviral treatment programme on public services in Malawi: access and survival on therapy among the police force. *Malawi Medical Journal* 2008; 20: 23-27.
21. World Health Organization. WHO Statistical Information System 2008; <http://www.who.int/countries/mwi/en/>.
22. National AIDS Commission. HIV and syphilis serosurvey and national HIV prevalence and AIDS estimates. 2007. Lilongwe: Malawi Ministry of Health.
23. Libamba E, Makombe S, Harries AD, et al. Scaling up antiretroviral therapy in Africa: learning from tuberculosis control programmes - the case of Malawi. *Int J Tuberc Lung Dis* 2005; 9: 1062-1071.
24. Malawi Ministry of Health. Antiretroviral therapy in the public and private sectors in Malawi: results up to 30th September, 2008. Lilongwe: HIV Unit. 2008.
25. Malawi Ministry of Health. Treatment of AIDS: Guidelines for the use of antiretroviral therapy in Malawi. Second Edition. Lilongwe: HIV Unit. Second Edition. 2006.
26. Libamba E, Makombe S, Mhango E, et al. Supervision, monitoring and evaluation of nationwide scale-up of antiretroviral therapy in Malawi. *Bull World Health Organ* 2006; 84: 320-326.
27. Lawn SD, Myer L, Orrell C, Bekker LG, Wood R. Early mortality among adults accessing a community-based antiretroviral service in South Africa: implications for programme design. *Aids* 2005; 19: 2141-2148.
28. Zachariah R, Fitzgerald M, Massaquoi M, et al. Risk factors for high early mortality in patients on antiretroviral treatment in a rural district of Malawi. *Aids* 2006; 20: 2355-2360.
29. Braitstein P, Brinkhof MW, Dabis F, et al. Mortality of HIV-1-infected patients in the first year of antiretroviral therapy: comparison between low-income and high-income countries. *Lancet* 2006; 367: 817-824.
30. Anderson PL, Kakuda TN, Kawle S, Fletcher CV. Antiviral dynamics and sex differences of zidovudine and lamivudine triphosphate concentrations in HIV-infected individuals. *Aids* 2003; 17: 2159-2168.
31. Cressey TR, Lallemand M. Pharmacogenetics of antiretroviral drugs for the treatment of HIV-infected patients: an update. *Infect Genet Evol* 2007; 7: 333-342.
32. Umeh OC, Currier JS. Sex differences in pharmacokinetics and toxicity of antiretroviral therapy. *Expert Opin Drug Metab Toxicol* 2006; 2: 273-283.


33. Marshall MM, McCormack MC, Kirk GD. Effect of cigarette smoking on HIV acquisition, progression, and mortality. *AIDS Education and Prevention* 2009; 21: 28-39

34. Hendershot CS, Stoner SA, Pantalone DW, Simoni JM. Alcohol use and antiretroviral adherence: review and meta-analysis. *J Acquir Immune Defic Syndr* 2009; August 7. (epub ahead of print)

35. Miguez-Burbano MJ, Lewis JE, Fishman J, Asthana D, Malow RM. The influence of different types of alcoholic beverages on disrupting highly active antiretroviral treatment (HAART) outcome. *Alcohol* 2009; 44: 366- 371.

36. Malawi Ministry of Health. ART in the public and private sectors in Malawi: results up to 31st December, 2007. Lilongwe: HIV Unit.2008.

Figure 1: Cumulative survival probabilities by gender



Time in months	0	6	12	18	24	30	36
<b>Number at risk</b>							
Males	2346	1451	911	581	341	217	121
Females	2324	1414	864	510	288	187	91
<b>Deaths</b>							
Males		255	53	22	5	3	3
Females		169	24	13	2	3	1

Abbreviations: ART, Antiretroviral therapy

**Table 1:** Socio-demographic and clinical characteristics and outcomes of healthcare workers, teachers, army and police personnel on ART, according to gender

Variables			Males		Females		p Value (X <sup>2</sup> )
	n	%	n	%	n	%	
<b>Age at starting ART (yrs)</b>							
19-34	1409	30.2	502	21.4	907	39.0	<0.001
35-44	2236	47.9	1231	52.5	1005	43.2	
45+	974	20.9	577	24.6	397	17.1	
Unknown	51	1.1	36	1.5	15	0.7	
<b>Occupation</b>							
Healthcare worker	1023	21.9	363	15.5	660	28.4	<0.001
Teacher	2637	56.5	1110	47.3	1527	65.7	
Army personnel	547	11.7	526	22.4	21	0.9	
Police personnel	463	9.9	347	14.8	116	5.0	
<b>WHO clinical Stage</b>							
1 or 2, CD4 ≤250	748	16.0	354	15.1	394	17.0	<0.001
3	2577	55.2	1236	52.8	1339	57.6	
4	1308	28.0	731	31.2	577	24.8	
Unknown	37	0.8	23	1.0	14	0.6	
<b>Stage defining condition</b>							
Other / unknown / PTB	3336	71.5	1628	69.4	1708	73.6	<0.001
Extra PTB	845	18.1	427	18.2	418	18.0	
Extra PTB	194	4.2	94	4.0	100	4.3	
Kaposi's sarcoma	292	6.3	197	8.4	95	4.1	
PMTCT	1	0.02	0	0	1	0.02	
<b>ART Facility</b>							
Public	4413	94.5	2213	94.3	2200	94.7	<0.001
Private	125	2.7	37	1.6	88	3.8	
Unknown	132	2.8	96	4.1	36	1.6	
<b>Time of ART Initiation</b>							
Before free ART	719	15.4	333	14.2	385	16.6	0.03
After free ART	3952	84.6	2013	85.8	1939	83.4	
<b>Outcome at end of observation</b>							
Alive on ART	3315	70.1	1574	67.1	1741	74.9	<0.001
Dead	547	11.7	341	14.5	206	8.9	
Lost to follow up	288	6.2	147	6.3	141	6.1	
Stopped ART	20	0.4	8	0.3	12	0.5	
Transferred out	500	10.7	275	11.8	224	9.6	
<b>Total</b>	4670	100	2346	50.2	2324	49.8	

ART, Antiretroviral Therapy; WHO, World Health Organisation; PTB, Pulmonary Tuberculosis; PMTCT, Prevention of Mother to Child Transmission

**Table 2:** Mortality and ART drop out rates and crude and adjusted rate ratios according to different background variables

Variables	Mortality				ART drop out			
	D/PYO	Rate	Rate Ratio [95% CI]	Adjusted Rate Ratio [95% CI] <sup>a</sup>	D/DYO	Rate	Rate ratio [95% CI]	Adjusted Rate Ratio [95% CI] <sup>a</sup>
<b>Sex</b>								
Male <sup>ref</sup>	334/ 2171	152.1	1.70 [1.45-2.06]	1.90 [1.67-2.16]	496/ 2298	216.5	1.44 [1.26-1.65]	1.61 [1.43-1.82]
Female	206/ 2269	90.8			359/ 2171	158.3		
<b>Age at ART initiation (yrs)</b>								
15-34	162/ 1258	130.8	1.07 [0.88-1.31]	1.15 [0.95-1.41]	252/ 1228	211.5	1.13 [0.97-1.32]	1.20 [1.02-1.40]
35-44	261/ 2141	121.9			421/ 2141	197.2		
45+	118/ 986	119.6	0.86 [0.70-1.02]	0.97 [0.79-1.21]	161/ 986	163.5	0.98 [0.82-1.17]	0.98 [0.82-1.16]
Unknown	0/ 73	0.0	0.67 [0.30-1.51]	0.61 [0.27-1.36]	11/ 73	150.2	0.82 [0.44-1.46]	0.71 [0.29-1.25]
<b>Occupation</b>								
Healthcare worker	118/ 891	132.4	1.13 [0.91-1.40]	1.22 [0.99-1.52]	165/ 891	182.8	0.98 [0.79-1.21]	0.96 [0.81-1.15]
Teacher	259/ 2552	117.2			518/ 2552	203.1		
Army personnel	71/ 590	120.4	1.03 [0.79-1.33]	0.73 [0.55-0.94]	84/ 590	142.2	0.70 [0.56-0.88]	0.53 [0.42-0.68]
Police personnel	89/ 407	144.8	1.24 [0.93-1.63]	0.94 [0.70-1.26]	90/ 407	221.1	1.08 [0.87-1.34]	0.87 [0.69-1.10]
<b>WHO clinical Stage</b>								
1 or 2, CD4 >250	49/ 720	68.0	0.66 [0.49-0.90]	0.66 [0.49-0.90]	86/ 720	119.4	0.68 [0.54-0.86]	0.70 [0.55-0.88]
3	258/ 2492	103.7			436/ 2492	174.9		
4	242/ 1187	203.8	1.88 [1.07-2.37]	1.91 [1.60-2.28]	329/ 1187	277.2	1.80 [1.37-2.38]	1.56 [1.35-1.80]
Unknown	0/ 39	0.0			4/ 39	103.2	0.69 [0.22-2.16]	0.53 [0.29-1.41]
<b>Stage defining condition</b>								
Other / unknown	394/ 3070	128.6			577/ 3070	188.0		
PTB	88/ 918	95.8	0.81 [0.64-1.02]		143/ 918	155.8	0.83 [0.69-1.0]	
Extra-PTB	28/ 136	132.7	1.12 [0.75-1.67]		36/ 136	183.8	0.98 [0.70-1.37]	
Kaposi's sarcoma	68/ 254	271.3	2.29 [1.7-2.98]		99/ 254	389.3	2.07 [1.67-2.58]	
PMTCT	0/ 2	0.0			0/ 2	0.0		
<b>ART Facility</b>								
Public	528/ 4205	125.1			838/ 4205	197.5		
Private	2/ 100	19.8	0.15 [0.04-0.60]		2/ 100	21.9	0.14 [0.05-0.34]	
Unknown	19/ 120	151.2	1.21 [0.76-1.91]		20/ 120	159.1	0.80 [0.53-1.25]	
<b>Time of ART initiation</b>								
Before first ART	88/ 1518	58.0	0.38 [0.30-0.47]		198/ 1518	129.9	0.58 [0.48-0.69]	
After first ART	458/ 2929	156.4			659/ 2929	225.0		
<b>Time since starting ART (months)</b>								
0-2	266/ 661	402.5			366/ 661	553.7		
3-5	120/ 810	150.4	0.40 [0.32-0.49]		196/ 810	241.9	0.41 [0.35-0.48]	
6-11	83/ 1183	70.2	0.17 [0.14-0.22]		128/ 1183	109.0	0.19 [0.16-0.23]	
12-17	44/ 730	59.9	0.15 [0.11-0.21]		66/ 730	116.9	0.90 [0.16-0.23]	

ART, Antiretroviral Therapy; WHO, World Health Organisation

Health Organisation; PTB, Pulmonary Tuberculosis; PMTCT, Prevention of Mother to Child Transmission; CI, Confidence interval  
 D/ PYO = deaths or art drop outs per person years of follow up; Rates are per 1000 person years of follow-up ref Reference group for rate ratios; a Adjusted using Poisson regression for age, occupation, clinical stage and time since starting ART; adjusted rate ratios are only shown for the variables found to be associated with the gender difference in mortality